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Abstract Obesity is recently acknowledged as an
important independent risk factor for kidney disease, in
which epidemiological evidence played a crucial role. This
risk is probably explained by intracellular lipid accumu-
lation in the kidney. Lifestyle factors such as physical
activity and diet play a role in the development of kidney
disease in several stages: development of obesity and the
metabolic syndrome, occurrence of obesity-related glo-
merulopathy, improvement of hemodialysis patients, and
prevention of graft dysfunction and graft loss after renal
transplantation. After the recent success of lifestyle inter-
vention to prevent diabetes, further research is needed to
show the effects of lifestyle changes to prevent and reduce
obesity-related morbidity, including chronic kidney
disease.
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Impaired renal function is strongly related to cardiovascular
disease and mortality [1]. One in every 200 adults suffers
from chronic kidney disease, and with growing obesity epi-
demic, this is likely to increase. This means that since kidney
disease takes a long time to develop, pre-clinical kidney
dysfunction is much more prevalent, and estimates in the
general population range from 5 to 11% [2, 3]. From 1985 to
2000, a tenfold increase in obesity-related glomerulopathy
was found [4]. Other publications relate factors of the met-
abolic syndrome to renal function [5]. Insulin resistance and
dyslipidemia are common factors in the early impairment of
renal function [6, 7]. Obesity is recently acknowledged as an
important independent risk factor for kidney disease, in
which epidemiological evidence played a crucial role.
Obesity is related to various forms of kidney disease [8],
including chronic renal failure [9] and end-stage renal dis-
ease (ESRD) [10, 11]. These associations reported by Hsu
et al. are presented in Table 1. In this paper we discuss this
evidence and outline perspectives for future lifestyle inter-
vention studies to protect the kidney and reduce related
cardiovascular disease and mortality.
Obesity as an independent factor
A novel aspect in the field of renal epidemiology is that
obesity is in itself an independent risk factor for the
development of kidney disease. Obesity and the metabolic
syndrome increase the risk for chronic kidney disease up to
three- to fourfold [9, 12]. At most half of this obesity-
related risk is explained indirectly by traditional risk fac-
tors like hypertension and type 2 diabetes [9, 11, 12],
leaving a large part unexplained.
Obesity is strongly related to hypertension and type 2
diabetes, and more in general to the metabolic syndrome.
The metabolic syndrome describes the clustering of car-
diovascular risk factors, including elevated blood pressure
and impaired glucose metabolism, but also central obesity,
elevated serum triglycerides and decreased serum HDL-
cholesterol. An important characteristic of the metabolic
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syndrome is the excess lipid accumulation in organs other
than adipose tissue, e.g., in liver, skeletal muscle, pancreas
and possibly in the kidney.
Epidemiological studies have played an important role
to identify the metabolic syndrome as a risk factor for
impaired kidney function. In 10,096 nondiabetic partici-
pants from the Atherosclerosis Risk in Communities
(ARIC) study who had normal baseline kidney function,
691 (7%) participants developed chronic kidney disease
(CKD) after 9 years of follow-up [12]. For subjects with
the metabolic syndrome, the multivariable adjusted odds
ratio (OR) of developing CKD was 1.43 (95% CI 1.18–
1.73). After adjusting for the subsequent development of
diabetes and hypertension during the 9 years follow-up, the
OR was 1.24 (95% CI 1.01–1.51). A case–control study
showed that overweight (BMI C 25 kg/m2) at age 20 was
associated with a significant threefold excess risk for
chronic renal failure, relative to BMI \ 25 [9]. This risk
was also threefold in individuals who were overweight at
age 20 but did not develop hypertension or diabetes.
Assessment of kidney disease
In the ARIC study described above, incident CKD was
defined as an estimated GFR (eGFR) \60 ml/min per
1.73 m2 after 9 years among those with an eGFR C60 ml/
min per 1.73 m2 at baseline [12]. The eGFR is usually
calculated with abbreviated Modification of Diet in Renal
Disease (MDRD) study equation [13], derived from serum
creatinine, age, sex and race. Serum creatinine can thus be
used as a plasma markers for kidney function, but is also
directly related to muscle mass and physical activity [14].
This may overestimate kidney function in physically
inactive individuals, and thereby underestimate the true
effect of obesity. Other studies report CKD or ESRD from
medical records. However, these endpoints do not represent
early kidney dysfunction due to competition with cardio-
vascular death. Additional measurements of urinary albu-
min may largely improve the identification of individuals at
increased risk for progressive renal disease [15].
Pathophysiology
Already in the 70s it was reported that obesity is related to
increased proteinuria [16]. Recently, an obesity-related
form of glomerulopathy was described [4]. This obesity-
related glomerulopathy was characterized by fewer lesions
of segmental sclerosis, more glomerulomegaly, and less
extensive foot process effacement (impaired glomerular
basement membrane integrity) than patients with classical
idiopathic focal segmental glomerulosclerosis.
Studies in mice show that intracellular lipid accumula-
tion in the kidney plays a role in high-fat diet induced
albuminuria, glomerular and tubular changes [17] and in
the age-related decline in kidney function, including
albuminuria and glomerulosclerosis [18]. The issue of
lipotoxicity has become especially relevant in the current
obesogenic society and the widely spread prevalence of a
high total and saturated fat intake.
Peripheral insulin resistance leads to hyperinsulinemia,
necessary to keep blood glucose levels within normal
limits. Such hyperinsulinemia may lead to overstimulation
in various other tissues that seem to preserve their normal
responsiveness to insulin, like the kidney [19]. This can
have harmful consequences. Animal experiments show that
excess insulin is associated with decreased endothelial
production of nitric oxide and increased oxidative stress.
Furthermore, excess insulin may promote the proliferation
of renal cells via growth factors and stimulation of growth
factor receptors [20]. Another mechanism that has attracted
renewed interest in the association between obesity and
altered renal hemodynamics. A number of early studies in
healthy subjects—performed in times that obesity was not
yet considered a risk factor for chronic kidney disease—
show that insulin may have detrimental effects on renal
hemodynamics (blood circulation in the kidney) [21, 22].
Nowadays it is known that also in the non-obese range
(BMI between 23 and 30 kg/m2), obesity is related to
hemodynamic changes [23]. Hemodynamic changes are
related to hyperfiltration and increased intraglomerular
pressure, podocyte injury, albuminuria (of FFA-rich albu-
min), and tubular cell injury. Several obesity related factors
are involved in hemodynamic changes, including hormonal
changes in the renin-angiotensin system, increased sym-
pathetic tone, and potentially increased circulating FFA
and leptin [24].
Table 1 Adjusted relative risk for end-stage renal disease (ESRD) by
body mass index (BMI) in 320,000 US subjects
BMI (kg/m2) Odds ratioa 95% CI Adjusted rate
per 100,000 person
years (95% CI)b
18.5–25.0 1 10 (9–12)
25.0–29.9 1.87 1.64–2.14 20 (18–22)
30.0–34.9 3.57 3.05–4.18 46 (40–53)
35.0–39.9 6.12 4.97–7.54 76 (60–91)
C40.0 7.07 5.37–9.31 108 (72–143)
Adapted from Hsu et al. [11]
a Adjusted for age, sex, race, education level, smoking status, history
of myocardial infarction, serum cholesterol level, proteinuria, hema-
turia, and serum creatinine level and multiphasic health checkup
period
b Adjusted for age, sex and race
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Lifestyle
Lifestyle factors such as physical activity [25] and diet [26,
27] are important modifiable factors for insulin resistance,
and have been associated with the risk of kidney disease
[28]. In the second National Health and Nutrition Exami-
nation Survey (NHANES II, n = 9,082), the risk of chronic
kidney disease was related to physical inactivity both with
and without adjustment for age, sex, race and body-mass
index [28]. The adjusted relative risk (RR) of inactive
versus very active was 2.2 (CI 1.3–3.8). This risk was
comparable to the RR in smokers of more than 20 ciga-
rettes a day versus never smokers (RR = 2.3; CI 1.3–4.2).
Lifestyle can play a role in the development of kidney
disease in several stages, as indicated in the Fig. 1. Obvi-
ously, lifestyle modulates the development of obesity and
the metabolic syndrome. Lifestyle contributes to the
development of type 2 diabetes and hypertension in several
ways, including energy intake, intake of saturated fat, salt
intake, and physical activity. Less clear is whether lifestyle
is related to the development of diabetic nephropathy, once
patients have developed type 2 diabetes, but it is very likely
that it is of influence on the development of obesity-related
glomerulopathy. After renal transplantation, the metabolic
syndrome is a prominent risk factor for post-transplantation
diabetes mellitus, chronic graft dysfunction, graft loss, and
patient death in renal transplant recipients [29]. Behav-
ioural changes to prevent weight gain may counteract the
post-transplant development of the metabolic syndrome
and thereby improve renal graft function and survival on
the long-term [30, 31].
A classical nutritional factor in renal function is salt
intake [32]. The effect of salt on renal function is related to
both high blood pressure and to a direct effect on renal
function, i.e., hemodynamic changes. The effect of sodium
intake on cardiovascular disease in Western societies
remains to be established, but urinary sodium/potassium
intake may be related to all-cause mortality in specific
groups of overweight subjects [33]. An in-depth review on
dietary salt intake and renal function reproduces that
variations in salt consumption are directly correlated with
albuminuria. Furthermore, an increase in salt consumption
is associated with an acute increase in glomerular filtration
rate, whereas a reduction in salt consumption may slow the
rate of renal function loss [34].
Likewise, many other lifestyle changes may be bene-
ficial. In nondialysis CKD, exercise can decrease micro-
albuminuria, protect from oxidative stress, reduce
inflammation, help to maintain body weight, increase
IGF-1 and increase renal function (for review by Moi-
nuddin and Leehey see [35]). In summary, exercise in
hemodialysis patients has been reported to enhance
insulin sensitivity, improve lipid profile, increase hemo-
globin, improve IGF-1 status, increase muscle strength,
decrease blood pressure, increase physical functionality
and improve quality of life. Combined aerobic exercise
and resistance training during dialysis improves muscle
strength, work output, cardiac fitness, and possibly dial-
ysis adequacy [36]. Also the maintenance or reduction on
body weight will be beneficial. Obesity in the early stages
of renal disease, and an increase in BMI after renal
transplantation are important risk factors for cardiovas-
cular disease and decline in renal function [37]. Very
little is known about other nutritional factors such as a
high saturated fat intake, low fibre intake and glycemic

























Fig. 1 Lifestyle can play a role
in the development of kidney
disease in several stages
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Perspectives
Pharmacological intervention to correct individual com-
ponents of the metabolic syndrome (including high blood
lipids, high cholesterol and elevated blood pressure) has
been proven beneficial to retard renal function decline.
Lifestyle intervention is a powerful tool to prevent or delay
progression from a healthy or prediabetic state to type 2
diabetes [38–41], with lifestyle being at least as effective as
pharmaceutical intervention [39, 42, 43]. Despite the
notification of lifestyle changes in the guidelines for
treatment of end-stage renal disease, the prescription of
physical activity or other lifestyle changes has been
severely hampered, among others by lack of convincing
evidence. The recent success of lifestyle changes in dia-
betes research has improved the support for lifestyle
changes as a tool to prevent and reduce obesity-related
morbidity, including chronic kidney disease.
The publication of the Kidney Disease Outcomes
Quality Initiative (K/DOQI) guidelines for the evaluation,
classification, and stratification of chronic kidney disease in
2002 [44] has raised awareness of chronic kidney disease
and greatly stimulated epidemiological research.
However, there are a number of unanswered questions in
the relation between lifestyle and improvement of renal
function. Whether lifestyle changes that benefit diabetes
will also benefit kidney function is unknown, but interest-
ing from a practical as well as an etiological point of view.
The role of dietary fats is unknown but the substitution of
saturated fats for unsaturated fats could have great potential
to prevent kidney disease as well as related cardiovascular
disease. Weight loss, or the prevention of weight gain, is a
very promising strategy. Weight loss has been the centre of
a lively debate, since in end-stage renal disease, an ele-
vated BMI is associated with a higher life expectancy [37].
With the need for dialysis, a catabolic process with mus-
cular atrophy and loss of stored fat begins. On the other
hand, obesity in the early stages of renal disease, and an
increase in BMI after renal transplantation are important
risk factors for cardiovascular disease and a decline in renal
function and should be prevented. It is very likely that
nutritional risk factors for cardiovascular disease, such as a
high saturated fat intake and low fibre intake are also rel-
evant for renal function, and certainly relevant in renal
patients due to their increased CVD risk.
At the same time, it is still unclear to what extent pre-
clinical kidney dysfunction is related to cardiovascular
events, and whether kidney-specific factors may increase
CVD risk in the general population. Also the relationship
between obesity-related factors such as inflammatory
parameters and early development of renal dysfunction
deserves attention. Decently designed epidemiological and
intervention studies are needed to fill these gaps in our
knowledge. A logistic obstacle in large scale studies might
be the collection of 24 h urine samples, which is necessary
to calculate creatinine clearance and quantitatively assess
renal function. With the awareness that early renal dys-
function is relatively common, projects like the recently
started LifeLines cohort study now include urine sampling
and demonstrate that this is feasible in daily epidemio-
logical practice [45]. In addition, especially in the current
obesogenic society, we need effective and tailored lifestyle
programs to prevent early renal dysfunction and related
cardiovascular disease, as well as to improve the long-term
success of renal transplantation.
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